ArticleNPJ precision oncology2025
Development and validation of a CAF-related signature for prognosis and therapy response in colorectal cancer: new insights on HSPB1.
Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advanced 3D cancer models for analyzing tumor-immune cell interaction and therapeutic response.Molecular cancer · 2026Review
- Integrative genomic profiling of iron homeostasis predicts clinical outcomes and identifies HAMP/hepcidin as a therapeutic target in colorectal cancer.Cell & bioscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Colorectal cancer (CRC) is a globally prevalent malignancy with high mortality rates. Cancer-associated fibroblasts (CAFs) are crucial in CRC progression and therapeutic response. This study systematically screened 22 CAF-related prognostic genes using single-cell and spatial transcriptomics analysis. By integrating 101 combinations of 10 machine learning algorithms, we developed and validated a comprehensive predictive model (CRPS) based on large-scale public and in-house datasets (1,541 patients in total), which exhibited superior prognostic predictability compared to 58 existing CRC prognostic models. CRPS score not only effectively evaluates biological functions, immune infiltration, and gene mutation levels, but also serves as a valuable tool for predicting immunotherapy efficacy in various cohorts (478 patients in total). In-house single-cell and spatial transcriptomics data, microarray cohort analysis, and experimental validation revealed that model key gene HSPB1 is closely associated with malignant transformation and subtype conversion of CAFs. In vitro and in vivo experiments further demonstrated that HSPB1-overexpressing CAFs enhance tumor cell malignancy, underscoring the therapeutic promise of targeting the HSPB1-CAF axis in CRC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.